Announcements Trials
Browse Landscape

Phase

Phase 4 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Pain 1Neoplasms 1Cancer Pain 1Breakthrough Pain 1

Interventions

Dexamethasone 56Metformin 50Cyclophosphamide 47Saline Solution 39Cytarabine 37Cisplatin 36Zoledronic Acid 34Letrozole 34Carboplatin 33Sodium Chloride 32Bupivacaine 31Docetaxel 30Bevacizumab 30Vincristine 29Methotrexate 29Fluorouracil 28Propofol 27Capecitabine 27Fentanyl 26Doxorubicin 26Rituximab 25Drug Therapy 25Dexmedetomidine 25Prednisone 23Paclitaxel 23Oxaliplatin 21Morphine 21Gemcitabine 21Radiotherapy 19Prednisolone 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × Ultracet × Clear all
NCT01968018 2013-10-23

A Study of Safety and Effectiveness of Ultracet in Patients With Chronic Cancer Pain

Janssen-Cilag Ltd.,Thailand

Phase 4 Completed
35 enrolled
Tumor-Agnostic

Neoplasms

NCT00576173 2010-04-28

An Open Label Study to Evaluate Safety, Tolerability and Clinical Utility of ULTRACET® (37.5mg Tramadol Hydrochloride/325mg Acetaminophen) for the Treatment of Breakthrough Pain in Cancer Patients

Johnson & Johnson Taiwan Ltd

Phase 4 Completed
60 enrolled

Cancer Pain, Pain, Breakthrough Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡